Short answer
Edgewise Therapeutics, Inc. (EWTX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$57M
- −58.7% YoY · −17.0% QoQ
- EPS (diluted)
- −$0.53
- −55.9% YoY · −15.2% QoQ
Source: XBRL data from the Edgewise Therapeutics, Inc. (EWTX) Q2 2026 10-Q on SEC EDGAR. USD.
Edgewise Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY; company has not generated revenue since inception
- Net loss $57.3M vs $36.1M YoY; operating expenses $61.9M vs $42.6M
- Best program EDG-7500 spending $8.1M, up $5.0M; EDG-15400 spending $3.4M, newly reported
- Cash used in operations $85.0M; cash, equivalents and securities $460.7M at June 30
- $1.55B Sevasemten-sale proceeds received July 10; Phase 3 EDG-7500 targeted for Q4 2026
Risk Factors
- Sevasemten sale created milestone-collection risk, with up to $1,100 million contingent on development, regulatory and commercial achievements
- Regulatory approval risk remains material because FDA, EMA and foreign review processes are lengthy and unpredictable
- EDG-7500 concentration risk, with business success substantially dependent on timely development, approval and commercialization
- Liquidity strengthened by $1,550 million upfront proceeds and $460.7 million in cash, equivalents and marketable securities at June 30, 2026
- Persistent loss risk, with $57.3 million quarterly net loss and $652.7 million accumulated deficit at June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Edgewise Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.